Mira Pharmaceuticals, Inc.
MIRA Nasdaq Pharmaceutical Preparations Financials FY2022–FY2025
Last close · Oct 23, 2026
$0.62
1.5%
Revenue
Total sales reported in the income statement.
$0.1M
40.3%
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$10.4M
Free cash flow
Cash from operations minus capital spending.
—
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
—
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On −$1.21 EPS (TTM)
What Mira Pharmaceuticals, Inc. does
No business description yet.
- Legal name
- MIRA PHARMACEUTICALS, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001493152-26-014001
0001904286
Revenue and margins
Mira Pharmaceuticals, Inc. had $0.1M of revenue in fiscal 2025, down 40.3% on the year before.
FY22
Revenue —
FY23
Revenue —
FY24
Revenue $0.2M
FY25
Revenue $0.1M
Q3 '23
Revenue —
Q4 '23
Revenue —
Q1 '24
Revenue —
Q2 '24
Revenue —
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.1M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net −4,739.1%
FCF —
FY25
Gross —
Operating —
Net −10,558.6%
FCF —
Gross
Operating
Net
FCF
Q3 '23
Gross —
Operating —
Net —
FCF —
Q4 '23
Gross —
Operating —
Net —
FCF —
Q1 '24
Gross —
Operating —
Net —
FCF —
Q2 '24
Gross —
Operating —
Net —
FCF —
Q3 '24
Gross —
Operating —
Net −5,407.1%
FCF —
Q4 '24
Gross —
Operating —
Net −6,298.4%
FCF —
Q1 '25
Gross —
Operating —
Net −8,335.5%
FCF —
Q2 '25
Gross —
Operating —
Net −17,880.2%
FCF —
Q3 '25
Gross —
Operating —
Net −7,246.5%
FCF —
Q4 '25
Gross —
Operating —
Net −11,246.8%
FCF —
Q1 '26
Gross —
Operating —
Net −2,561.7%
FCF —
Q2 '26
Gross —
Operating —
Net −3,443.0%
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY22
Net income −$7.1M
FY23
Net income −$12.0M
FY24
Net income −$7.9M
FY25
Net income −$10.4M
Q3 '23
Net income −$3.6M
Q4 '23
Net income −$5.8M
Q1 '24
Net income −$1.7M
Q2 '24
Net income −$1.7M
Q3 '24
Net income −$2.0M
Q4 '24
Net income −$2.4M
Q1 '25
Net income −$1.8M
Q2 '25
Net income −$1.5M
Q3 '25
Net income −$1.1M
Q4 '25
Net income −$6.0M
Q1 '26
Net income −$1.2M
Q2 '26
Net income −$1.2M
FY22
Diluted EPS −$0.40
FY23
Diluted EPS −$0.85
FY24
Diluted EPS −$0.51
FY25
Diluted EPS −$1.35
Q3 '23
Diluted EPS −$0.26
Q4 '23
Diluted EPS −$0.39
Q1 '24
Diluted EPS −$0.15
Q2 '24
Diluted EPS −$0.11
Q3 '24
Diluted EPS −$0.14
Q4 '24
Diluted EPS −$0.11
Q1 '25
Diluted EPS −$0.11
Q2 '25
Diluted EPS −$0.09
Q3 '25
Diluted EPS −$1.18
Q4 '25
Diluted EPS $0.03
Q1 '26
Diluted EPS −$0.03
Q2 '26
Diluted EPS −$0.03
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY22
Return on capital —
Return on equity —
Return on assets −822.5%
FY23
Return on capital —
Return on equity −634.3%
Return on assets −413.9%
FY24
Return on capital —
Return on equity −238.9%
Return on assets −199.9%
FY25
Return on capital —
Return on equity −165.9%
Return on assets −149.0%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY22
Free cash flow —
FY23
Free cash flow —
FY24
Free cash flow —
FY25
Free cash flow —
FY22
Cash from operations −$5.6M
Capital spending —
FY23
Cash from operations −$4.5M
Capital spending —
FY24
Cash from operations −$5.6M
Capital spending —
FY25
Cash from operations −$4.7M
Capital spending —
Cash from operations
Capital spending
Q3 '23
Cash from operations −$1.8M
Capital spending —
Q4 '23
Cash from operations −$1.0M
Capital spending —
Q1 '24
Cash from operations −$1.0M
Capital spending —
Q2 '24
Cash from operations −$0.9M
Capital spending —
Q3 '24
Cash from operations −$1.8M
Capital spending —
Q4 '24
Cash from operations −$1.8M
Capital spending —
Q1 '25
Cash from operations −$1.6M
Capital spending —
Q2 '25
Cash from operations −$0.8M
Capital spending —
Q3 '25
Cash from operations −$1.1M
Capital spending —
Q4 '25
Cash from operations −$1.1M
Capital spending —
Q1 '26
Cash from operations −$1.2M
Capital spending —
Q2 '26
Cash from operations −$1.2M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
Mira Pharmaceuticals, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY22
Diluted shares 0.02B
FY23
Diluted shares 0.01B
FY24
Diluted shares 0.02B
FY25
Diluted shares —
Balance sheet
Cash, debt and the ratios that show how comfortably Mira Pharmaceuticals, Inc. can carry it.
FY22
Cash $0.4M
Debt —
FY23
Cash $4.6M
Debt —
FY24
Cash $2.8M
Debt —
FY25
Cash $11.0M
Debt —
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.4M | $4.6M | $2.8M | $11.0M |
| Current ratio | 0.4x | 8.7x | 4.0x | 15.8x |
| Quick ratio | 0.4x | 8.7x | 4.0x | 15.8x |
| Total assets | $0.9M | $4.9M | $2.9M | $11.1M |
| Total liabilities | $1.5M | $0.6M | $0.7M | $0.7M |
| Shareholders' equity | −$0.6M | $4.4M | $2.2M | $10.4M |
| Net debt (− = net cash) | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✓ | ✕ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — | — |
| Current ratio rose | — | ✓ | ✕ | ✓ |
| Share count didn't rise | — | ✓ | ✕ | — |
| Gross margin rose | — | — | — | — |
| Revenue rose relative to assets | — | — | — | ✕ |
| F-score | — / 3 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −169.4% | −257.3% | −58.4% | −82.5% |
| Altman Z'' | — | — | — | — |
4 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | $0.2M | $0.1M |
| Net interest income | — | — | $0.2M | $0.1M |
| Research and development | $2.4M | $1.6M | $3.3M | $1.7M |
| Interest expense | $0.0M | $3.5M | −$0.2M | — |
| Net income | −$7.1M | −$12.0M | −$7.9M | −$10.4M |
| Net income to common | — | — | −$7.9M | −$32.0M |
| Diluted EPS | −$0.40 | −$0.85 | −$0.51 | −$1.35 |
| Diluted shares | 0.02B | 0.01B | 0.02B | — |
| Cash flow | ||||
| Cash from operations | −$5.6M | −$4.5M | −$5.6M | −$4.7M |
| Stock-based compensation | $1.3M | $2.6M | $1.9M | $6.3M |
| Balance sheet | ||||
| Cash and short-term investments | $0.4M | $4.6M | $2.8M | $11.0M |
| Current assets | $0.5M | $4.9M | $2.9M | $11.1M |
| Current liabilities | $1.4M | $0.6M | $0.7M | $0.7M |
| Total assets | $0.9M | $4.9M | $2.9M | $11.1M |
| Total liabilities | $1.5M | $0.6M | $0.7M | $0.7M |
| Shareholders' equity | −$0.6M | $4.4M | $2.2M | $10.4M |
| Margins | ||||
| Net margin | — | — | −4,739.1% | −10,558.6% |
| Net interest share of revenue | — | — | 100.0% | 100.0% |
| Returns | ||||
| Return on equity | — | −634.3% | −238.9% | −165.9% |
| Return on assets | −822.5% | −413.9% | −199.9% | −149.0% |
| Return on tangible equity | — | −273.9% | −357.0% | −307.9% |
| Growth | ||||
| Revenue growth | — | — | — | −40.3% |
| Share count change | — | −20.7% | 10.9% | — |
| Financial health | ||||
| Current ratio | 0.4x | 8.7x | 4.0x | 15.8x |
| Quick ratio | 0.4x | 8.7x | 4.0x | 15.8x |
| Capital allocation | ||||
| Stock comp / revenue | — | — | 1,159.2% | 6,383.4% |
| Quality scores | ||||
| Accruals ratio | −169.4% | −257.3% | −58.4% | −82.5% |
Source: SEC EDGAR XBRL filings (CIK 0001904286). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.